Pharmacies want comparative data before adding new drugs to their formulary. Either the "new drug" has comparative data to prove that they are better than what's available, or they don't get approved. This will be the end of "me-too" drugs! http://www.mmm-online.com/payersmanaged-markets/infographic-what-payers-want-from-pharma/article/634114/
Don't expect miracles here, nothing I've seen so far shows me that LU has the talent and competency to influence managed care. Once Onfi goes generic the train will start unloading the hogs at the slaughter house.
And remember, on the psych side, they have 0 influence on managed care. All determined by Japanese counterparts.
All the while our CEO is cozy in Copenhagen... doing his little video snippets... it's interesting we are making up over 50% of the annual revenue in America for Global LU and you only hear from him at meetings in video snips and videos when he's so happy you lined his pockets with a few million dollars bonus for his 200million dollar beat which he had nothing to do with. Can't wait to hear the spin in Dallas the day after the super bowl. When Trump starts coming after pharma in his upcoming weeks, our CEO will be one of the first to appear on the Hill testifying to why Northera costs many patients 3-12k a month and without these assistance programs nobody can afford it. Despite the cost it's interesting that the company still cannot articulate any official patient assistance program to help pay for the medication. Meanwhile we exceeded our target by 200 million dollars and left people without the medication they needed. Rings pretty hollow. LU used to be about making sure nobody was left behind and had a great story that really engaged healthcare providers as a different company. It all started changing the day this CEO came along.
this company jumped out a window over 10 years ago. Once they pissed away the Lexapro money and had to take a handout from Japan just to develop their own compounds the writing was on the wall. After falling 98 stories, they are now just 3 floors above the sidewalk. The 'splat' comes when Onfi goes generic.
Excellent post however your brethren on the psych side don't realize that we don't even bring in enough money to pay our way. Neuro pays the bills here and before long, they won't pay their own way either.
Yep Lundbeck needed several things to go right in the past 5-10 years; all missed. 1. European psych market continue to perform at early 2000's level. 2. Trintellix becomes a 1-2 billion dollar blockbuster with differentiating indication (cognition). 3. Northera lives up to inflated expectations (600 million peak sales). 4. Idalopirdine approval. The ONLY good surprise has been Onfi and Xenazine.
Great post! Lundbeck can't see its way out of a box! These drugs have the absolute worse managed care of any company out there! And our "co-pay" options are a joke! On the psych side Trintellix is unique but the company has failed to provide the data to support that. Rexulti is a copy cat drug and AM is nothing special. The company doesn't explain how they reached the billion goal and not paying reps! Sound familiar? If not it is the big pharma mentality
